CLSI M24 A2 : 2ED 2011

Abstract
Committee Membership
Foreword
1 Scope
2 Standard Precautions
3 Terminology
4 Antimycobacterial Susceptibility for Mycobacterium
  tuberculosis Complex
5 Susceptibility Testing of Nontuberculous Mycobacteria
6 Susceptibility Testing of Aerobic Actinomycetes
References
Appendix A - Susceptibility Testing of Mycobacterium
             tuberculosis Complex to Second-line Drugs
             Using Commercial Shorter Incubation
             Liquid Media Systems
Appendix B - Suggested Approach to Mycobacterium
             tuberculosis Complex Susceptibility
             Testing in Resource-Limited Countries
Appendix C - Example Illustrating Drug Calculation for
             Meropenum Trihydrate
Appendix D - Preparation and Plating of 7H10 and 7H11
             Agar Medium
Appendix E - Preparation of Media With Drug-Containing Disks
Appendix F - Preparing 7H10/H11 Agar With Liquid Drug
Appendix G - McFarland 0.5 Barium Sulfate Turbidity Standard
Appendix H - Determining Percentage of Resistance
Appendix I - Drugs Available for Susceptibility Testing
             of Mycobacterium tuberculosis Complex
             Using Commercial Shorter Incubation Liquid
             Media Systems Cleared for Use by the US Food
             and Drug Administration and Their Equivalence
             in the Agar Proportion Method
Appendix J - Agar Disk Elution Method for Mycobacterium
             haemophilum
Appendix K - Expected Antimicrobial Susceptibility Patterns
             of the Most Commonly Isolated Nocardia
The Quality Management System Approach
Related CLSI Reference Materials

Gives protocols and related quality control parameters and interpretive criteria for the susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes.